The ANIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ANIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ANIP Detailed Price Forecast - CNN Money||View ANIP Detailed Summary - Google Finance|
|View ANIP Detailed Summary - Yahoo! Finance||View ANIP Stock Research & Analysis - Zacks.com|
|View ANIP Trends & Analysis - Trade-Ideas||View ANIP Major Holders - Barrons|
|View ANIP Call Transcripts - NASDAQ||View ANIP Breaking News & Analysis - Seeking Alpha|
|View ANIP Annual Report - CompanySpotlight.com||View ANIP OTC Short Report - OTCShortReport.com|
|View ANIP Fundamentals - TradeKing||View ANIP SEC Filings - Bar Chart|
|View Historical Prices for ANIP - The WSJ||View Performance/Total Return for ANIP - Morningstar|
|View the Analyst Estimates for ANIP - MarketWatch||View the Earnings History for ANIP - CNBC|
|View the ANIP Earnings - StockMarketWatch||View ANIP Buy or Sell Recommendations - MacroAxis|
|View the ANIP Bullish Patterns - American Bulls||View ANIP Short Pain Metrics - ShortPainBot.com|
|View ANIP Stock Mentions - StockTwits||View ANIP Stock Mentions - PennyStockTweets|
|View ANIP Stock Mentions - Twitter||View ANIP Investment Forum News - Investor Hub|
|View ANIP Stock Mentions - Yahoo! Message Board||View ANIP Stock Mentions - Seeking Alpha|
|View Insider Transactions for ANIP - SECform4.com||View Insider Transactions for ANIP - Insider Cow|
|View ANIP Major Holdings Summary - CNBC||View Insider Disclosure for ANIP - OTC Markets|
|View Insider Transactions for ANIP - Yahoo! Finance||View Institutional Holdings for ANIP - NASDAQ|
|View ANIP Stock Insight & Charts - FinViz.com||View ANIP Investment Charts - StockCharts.com|
|View ANIP Stock Overview & Charts - BarChart||View ANIP User Generated Charts - Trading View|
Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Thursday October 18, 2018
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ANI Announces Launch of Authorized Generic of Brethine®
Posted on Tuesday October 16, 2018
BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market. ANI acquired the NDA for Brethine® (terbutaline sulfate) tablets in December 2016. Arthur S. Przybyl, ANI's President and CEO stated, "ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs.
ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
Posted on Thursday October 04, 2018
BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®. The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. Atacand HCT® is indicated for the treatment of hypertension.
ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Posted on Thursday September 27, 2018
BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/cantor7/anip/ and will be archived and available through the link through January 1, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.